Forward normalized EPS valuation using Q3 FY27 guided EPS midpoint annualized and existing P/E multiples. Includes conservative full potential dilution from the August customer warrant when economically dilutive, with exercise proceeds; vesting is contingent through FY33. This estimates exercise dilution, not option time value.
as of 2026-10-06
Built with Modeledge MCP
Connect your MCP client to research filings and earnings calls, then build a living financial model like this one.